The purpose of the Biostatistics Core is to provide design and analytic support to SPORE Projects, Developmental Projects, and other Cores. This core has three specific aims. 1. To provide biostatistical expertise for the planning, conduct, analysis, and reporting of laboratory, animal, clinical, and epidemiological studies for SPORE projects and developmental projects. The Biostatistics Core will work with SPORE researchers on protocol and experimental design, and will provide estimates of sample size and statistical power. The Core will advise researchers about optimal methods for monitoring ongoing studies. The Core will provide statistical analyses of completed experiments, and participate in manuscript preparation. 2. To provide or recommend supporting computational infrastructure, including computer databases, statistical computer packages, publicly available statistical programs and data sharing between computers or databases. Because an effective informatics infrastructure is critical to the functioning of the SPORE, the Biostatistics Core will work to assure that the storage and accessibility of data used and generated by the SPORE is efficient and effective. The Biostatistics Core will support efficient management of data resources by consulting on database design, helping to design efficient data collection methods and conducting audits of data quality. 3: To provide consulting and statistical education to SPORE researchers. In addition to formal collaborative efforts, the Biostatistics Core will be available for ongoing, informal consultation with researchers over the duration of the SPORE. In addition the Biostatistics Core will work with investigators within the DF/HCC Skin Cancer SPORE, other Skin Cancer SPOREs and Cooperative Groups to attempt to build a prognostic and predictive model for melanoma patients with a web-based statistical product that will help physicians define the prognosis and select the optimal therapy for individual patients with various stages of melanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Jain, Salvia; Stroopinsky, Dina; Yin, Li et al. (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354-62
Lee, Jonathan J; Granter, Scott R; Laga, Alvaro C et al. (2015) 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol 28:218-29
Bhela, Siddheshvar; Kempsell, Christine; Manohar, Monali et al. (2015) Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol 194:2180-9
Lee, Jonathan J; Cook, Martin; Mihm, Martin C et al. (2015) Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. Oncotarget 6:37995-8004
Watanabe, Rei; Gehad, Ahmed; Yang, Chao et al. (2015) Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med 7:279ra39
Kirsch, Ilan R; Watanabe, Rei; O'Malley, John T et al. (2015) TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 7:308ra158
Litvinov, Ivan V; Netchiporouk, Elena; Cordeiro, Brendan et al. (2015) The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clin Cancer Res 21:2820-9
Yazawa, Erika M; Geddes-Sweeney, Jenna E; Cedeno-Laurent, Filiberto et al. (2015) Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. J Invest Dermatol 135:1849-62
Lezcano, Cecilia; Lee, Chung-Wei; Larson, Allison R et al. (2014) Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol 27:1193-202

Showing the most recent 10 out of 129 publications